Navigation Links
Antisense Pharma: Promising Phase IIb Results of Targeted Therapy,with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplastic astrocytoma, AP 12009 as a monotherapy is actually clearly superior to temozolomide,” Prof. Albert Wong, M.D., Stanford University, California, U.S.A. commented on the international Phase IIb study with the TGF-beta 2-inhibitor AP 12009, under development by Antisense Pharma. Prof. Wong discussed the results of the study in the poster discussion session on central nervous system tumors at the 43rd Annual Meeting of the American Society of Clincal Oncology (ASCO) in Chicago, USA, this month.

The Phase IIb study AP 12009-G004 is an open-label, randomized, actively-controlled, parallel-group dose-finding study to evaluate the efficacy and safety of two doses of AP 12009 in adult patients with recurrent high-grade glioma. Efficacy endpoints were tumor response assessed by central blinded MRI reading and survival. At 29 international clinical centers 134 evaluable patients (39 with anaplastic astrocytoma, AA, WHO grade III and 95 with glioblastoma, GBM, WHO grade IV) have been randomized to three arms: AP 12009 10 ?M, AP 12009 80 ?M and chemotherapy (Temozolomide or PCV) as a control. AP 12009 was administered intratumorally via one catheter as continuous high-flow microperfusion over a 7-day period every other week for up to 6 months on an outpatient treatment basis (1, 2). Post-study follow-up for survival, long-term tumor response, and safety is still ongoing. Analysis of the core phase for AA patients is completed.

Tumor response was assessed according to Macdonald criteria. The response rate for AP 12009 10 ?M in anaplastic astrocytoma patients steadily increased in the course of 14 months, whereas in the chemotherapy treatment arm a transient peak of the response rate at 6 months was not sustainable and decreased to zero at 14 months. Response rates were higher in the AP 12009 10 ?M group compared to the AP 12009 80 ?M group. The
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Lorus Therapeutics Announces Scientific Presentations for Lead Antisense and siRNA Drug Candidates at International Cancer Conference
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
6. Promising Data on Cognitive Effects of Safinamide in Early Parkinsons Disease
7. Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia
8. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
(Date:5/16/2008)...Enables First-Ever PEGylation of a Small Molecule ...tivity, SAN CARLOS, Calif., May 16 /PRNewswire-Fi...nnounced initial results today from a Phase 1,stud...ws significant,anti-tumor activity in patients wit...ates that Nektar,s small molecule PEGylation techn...
(Date:5/16/2008)...y 16 /- Veridex, LLC announced today ...ation of America Holdings,(LabCorp), has commercia...ate cancer. The new assay uses the biological spec...etecting the methylation of the gene,GST-Pi. Methy...ily in,cancer. Veridex is developing the methylati...
(Date:5/16/2008)...tes Statistically Significant Reductions in Select... Abstract to be published in 2008 Proceedings of t...linical Oncology, SAN DIEGO, May 16 /PRNewswire-F... ANX ) announced today that, in a registrational ...d a statistically significant reduction,in general...
(Date:5/15/2008)....J., May 15 /- Eisai Corporation of N...clinical data abstracts about,compounds in the com...eclinical oncology research have been accepted for...erican Society of Clinical Oncology (ASCO),taking... wide variety of abstracts on Eisai marketed produ...
Breaking Medicine Technology:Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 2Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 3Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 4Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings 5ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 2ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 3ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 4ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Epigenetic changes discovered in major psychosis 2461 1Epigenetic changes discovered in major psychosis 2461 2Breaking Boundaries Program Honors Colorectal Cancer Survivors for Outstanding Leadership Achievements 14021 1Breaking Boundaries Program Honors Colorectal Cancer Survivors for Outstanding Leadership Achievements 14021 2Breaking Boundaries Program Honors Colorectal Cancer Survivors for Outstanding Leadership Achievements 14021 3Breaking Boundaries Program Honors Colorectal Cancer Survivors for Outstanding Leadership Achievements 14021 4Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 14019 1Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 14019 2Highmark Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 14019 3Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon 14017 1Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon 14017 2Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon 14017 3Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon 14017 4Atlanta Falcons Linebacker Keith Brooking Prepares to Run for Something Better at ING Georgia Marathon 14017 5
...BUSINESS WIRE)--Apr 17, 2007 -,Seattle Genetics, I...en presentations by the company and its collaborat...ociation for Cancer Research,(AACR) demonstrating ...-drug conjugate (ADC) technology and cancer produc... to cell-killing drugs.,Seattle Genetics, ADC tech...
...ewswire/ -- Micell,Technologies announced today th...ts supercritical fluid (SCF) surface modification,... Society for,Biomaterials 2007 Annual Meeting, Apr...s describe use of Micell and PNNL,s, 2006 R&D,...-eluting stents,containing crystalline drugs, such...
Other Medicine Technology:Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR 2Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR 3Seattle Genetics Highlights Data on its Proprietary Antibody-Drug,Conjugate Technology at AACR 4Micell Technologies Presents Data on Novel Drug-Eluting Stents 2Micell Technologies Presents Data on Novel Drug-Eluting Stents 3
(Date:5/16/2008)...nne,s Bed & Back; Merger Sets Up Healthy Back... Chain, LORTON, Va., May 16 /PRNewswire/ -- Healt...me and workplace back wellness created an,ergonomi...of its rival,JoAnne,s Bed & Back. Healthy Back,s ...nues of $40million. JoAnne,s 16 mid-Atlantic store...
(Date:5/16/2008)...ewswire-USNewswire/ -- This release is,being sent ...ction with the,National Cancer Institute, part of ...t the American Society of Clinical,Oncology meetin...t practice,in about 25 percent of patients with co...o the way colorectal cancers will be staged., * T...
(Date:5/16/2008)...rers gain benefit from calcitriol, an oral form ,...ing activated vitamin D may cut the risk of death ...disease by about one quarter, a new study suggests... patients, those being treated with calcitriol, an...ll risk of death lowered by 26 percent when compar...
(Date:5/16/2008)...o Raise $38 Million for Life-threatening,Disease, ...Walkers in nearly,every state will raise funds for...by participating in GREAT STRIDES, the largest nat...on announced today., May is National Cystic Fibro...eatening genetic disease that causes fatal lung in...
Breaking Medicine News(10 mins):Health News:The Back Wars Come to a Close 2Health News:New Method Proposed for Determining Which Patients Should Get Treatment for Colorectal Cancer 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2Health News:GREAT STRIDES Walks for Cystic Fibrosis Slated for 47 States This Weekend 2
...as of George Washington University, while presenti..., chopping of vegetables to bite size pieces and c...the reasons that our teeth are growing crooked and...ped teeth may be a direct result of evolution than...
... recent study researchers suggest that women drink...e past // have reported drinking wine is good for ...tential health benefits of alcohol has been done o...te amounts of wine seems to be good for the heart....
...and athletes who live their lives by their sports ...heir oral health for sake of athletic achievements...issue of Journal General Dentistry, most harm caus...nade, sports drinks and energy drinks. At times th...
... is a potentially life-threatening infection for p...on, doctors often prescribe an inhaled drug called...this drug is controversial because some patients e...hi, which causes severe coughing and reduced lung ...
Other Medicine News:
Ultralight Jarrod Goggles have set the standard for comfort in leaded eyewear! Nonslip soft silicone saddle nose bridge. Monel forehead rest brow bar supports better and lasts longer. Adjustable elas
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection.
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation
Portable shields for your safety and convenience.
Medicine Products: